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Heart failure (HF) is a chronic heterogeneous clinical syndrome that is unified by
the presence of clinical signs and symptoms
of congestion and by the difficulty of its diagnosis and management. Its prevalence, of
6.5 million people in the USA,1 is rising due
to an increasing incidence and to advances in
medical, interventional and device therapies
which extend the longevity of the affected
patients. Despite these advances, HF is characterised by intermittent and recurrent exacerbations, which are associated with high
morbidity, mortality and costs. The estimated
costs of HF care are 40 billion dollars annually
in the USA, from which >10 billion are due
to hospital admissions after presentation to
an emergency department (ED).2 Currently,
the care paradigm for patients with HF is
dichotomous, divided between the care of
patients with chronic compensated HF in the
outpatient setting and acute decompensated
heart failure (ADHF) in an inpatient setting.
Patients with compensated HF are managed
longitudinally in outpatient clinics, including
HF cardiology clinic, general cardiology clinic
and primary care clinics. Traditionally, each
of these clinics exist as independent ‘silos’
with limited direct communication between
them. Furthermore, they are designed,
staffed and supplied to provide traditional
outpatient care, with limited ability to intervene in a rapid or invasive way. This is clearly
focused on the evaluation and management
of compensated patients.
Perhaps it is not surprising that ADHF
accounts for over 1 million annual ED
presentations in the USA.2 When a patient
with ADHF presents to any of the above-
mentioned clinical offices, there is a limited
infrastructure and capabilities to address their
acute needs. For a mild decompensation,
oral diuretics may be adjusted with a plan for
follow-up laboratories and phone calls. For
a more severe decompensation, a patient
may be directly admitted to the hospital or

referred to the nearest ED. More than 90%
of all patients with ADHF presenting to an ED
are admitted to the hospital, for an average
length of stay of 5 days.2 Even though inpatient admission for decongestion is the major
throughput for ADHF care, there have not
been significant changes in the ED or inpatient care of these patients for the past several
decades. This is reflected in the most current
American College of Cardiology/American
Heart Association (AHA) guidelines from
2013 and subsequent update in 2017,3 4 which
do not give guidance for risk stratification of
ADHF, nor the appropriate care setting of
therapy. What recommendations are available primarily focus on in-hospital management with decongestion with an intravenous
diuretic, home HF medical therapy should
be continued, and for discharge planning.
Indeed, the high readmission and complications rates, including death, may be due
to the lack of clinical trials data and standardised practices of ADHF management in
the ED and as inpatients.
We propose that an alternative paradigm
for the long-term management of patients
with compensated HF and ones with ADHF
is needed to improve outcomes of patients
with HF at lower costs—the 360o HF centre.
This should be a patient-centred comprehensive, inpatient and outpatient, care model
that uses a care coordinator to manage
patients with HF (figure 1). Chronic care
models using multidisciplinary healthcare
professionals, such as care coordinators, self-
care/wellness educators, group therapy/
education, dietitians, clinical pharmacists
and social workers, have been effective in
other chronic disease models.5 6 On the
outpatient side, where the patients with HF
spend the majority of their time, the model
must be centred around the patient who will
be coupled with a care coordinator. A meta-
analysis of 47 randomised studies of care
coordination after hospital discharge across
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Figure 1 360o heart failure centre: a patient-centred comprehensive model for the care for congestive heart failure (HF) .
The care is centred around the patient with distance of different services representing the frequency and level of support. The
patient is in the centre of the inner circle and can receive home services, including monitoring and home nursing (capable
of intravenous (IV) or subcutaneous diuresis (SQ)). The care coordinator, through whom all supportive services provide
coordinated care, manages all aspect related to the HF management of the patient. Additional services, including dietary, social
work and pharmacy, have close regular follow-up and interventions with the patient. Other services, including occupational
health, physical therapy and cardiac rehabilitation, can be used on as-needed basis. Patient continues to follow closely with
primary care practitioner (PCP) and cardiology clinics (capable of IV or SQ diuresis).

a variety of diagnoses, including HF, showed reduction
in readmissions, a trend toward reduction in mortality
and improvement in patient satisfaction.7 Indeed, the
AHA recommends that care coordination, among other,
is essential for patients with HF being discharged from
the hospital after ADHF admission.8 The care coordinator, who may be a mid-level practitioner, like a HF
nurse practitioner or physician assistant, will be deeply
familiar with the medical, mental, social and financial
condition of the patient with HF and be the direct
point of contact for the patient and other providers
for any chronic or acute medical status changes. The
care coordinator must have multidisciplinary support
staff previously shown to improve clinical outcomes
for patients with HF including a dietitian,9 10 a clinical pharmacist11 12 and a social worker,13 who can be
shared with the patient’s primary care physician. Diets,
like Dietary Approaches to Stop Hypertension and
the Mediterranean diet, have shown benefits in the
2

secondary HF prevention and in reducing the mortality
in women with HF.9 10 Several randomised controlled
studies performed in multiple continents found that
integrating clinical pharmacists in the care of patients
with HF results in reduction in hospitalisations, either
from HF or other, which has led to the recommendation
that clinical pharmacists be part of the team caring for
patients with HF by the Heart Failure Society of America
and American College of Clinical Pharmacy Cardiology
Practice and Research Network.11 12 A major predictor
for poor outcomes and hospital readmissions for HF
are inadequate social resources and support,14 which
can be addressed by a social worker. A randomised trial
by O’Donnell et al,13 found that a social worker-lead
palliative care intervention can facilitate end-of-life and
goals of care discussions in patients with advanced HF.
Therefore, we propose that these multidisciplinary care
providers can be strategically used for:
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Dietary education which must take place in the
patient’s home and while grocery shopping to truly
be effective in promoting durable lifestyle change.
►► A clinical pharmacist is instrumental in reviewing
patients’ medication lists to help evaluate for possible
deleterious interactions between different medications not usually prescribed by HF practitioners,
and suggest alternatives to existing medications, like
sodium–glucose cotransporter-2 inhibitors in patients
with diabetes.
►► A social worker is essential to help the patient and
provider navigate through the multitude of financial
and logistical barriers to providing better options for
medical, mental and financial health.
Additional services such as telehealth and/or
CardioMEMS should be available to monitor patients
with HF at home. All patients with HF can benefit from
daily monitoring for early detection of deviations in
established haemodynamic parameters. CardioMEMS
was indicated for high-risk patients, defined as having
advanced heart failure with New York Heart Association
III symptoms and a HF hospitalisation in the past year by
the USA Food and Drug Administration.15 More recently,
‘real-world’ studies showed more significant reduction
in pulmonary artery pressures than the initial study and
significant reduction in HF hospitalisations.16 17 Home
telehealth monitoring of weight, blood pressure and
heart rate, which also has been shown to reduce mortality
in patients with HF,18 19is appropriate for all remaining
patients. When a patient with HF is identified as having
a persistent unfavourable change in their monitoring
parameters by telehealth and/or CardioMEMS, such as
an increase in weight or pulmonary capillary wedge pressures, they should be contacted to evaluate for correlation with worsening in symptoms.
A 360° HF centre should provide more extensive and
interventional outpatient services for patients with HF
than a traditional cardiology clinic. When adjustment of
oral diuretics is ineffective, elected patients with HF should
be treated with intravenous or subcutaneous infusions of
diuretics at home (through home services) or in clinic.
This, however, requires home and/or clinic services that are
enabled to administer and monitor the effects of 20 21intravenous and/or subcutaneous (for review, see Afari et al22)
diuretics. In the case of subcutaneous administration,
patients would need to have their blood drawn (potentially
before and 1–2 days after administration) to evaluate for
changes in renal function and electrolytes. With intravenous administration, patients would also need to be monitored for vital sign changes for 3 hours after administration
and repeated blood draws. The combination of close monitoring via telehealth and/or CardioMEMS with the appropriate intervention of a care coordinator in HF clinic and
at home will help with the early management of HF decompensation, thus averting ED presentation and hospital
admissions usually associated with this patient population.
Patients with ADHF who present to the ED should be
evaluated by the ‘six-axis model’23 and if determined to
►►
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be low risk could be discharged through close collaboration between the ED and a 360o HF centre. Patients with
ADHF and high-risk features should be admitted to either
a medical service with HF specialist consultation or to a
primary HF service for further management. The inpatient ADHF care should focus on symptomatic improvement of congestion, diuresis to reach euvolaemia and
evaluation for potential causative factors of the ADHF
presentation, including cardiac or non-cardiac comorbidities, disease progression or dietary/medication non-
adherence. The 360o HF centre care coordinator and
multidisciplinary team would be well equipped to create
an action plan to address such specific HF patient’s
causative factors and to initiate palliative care consultation when appropriate. Continuity of care with the care
coordinator and pharmacist in the 360o HF centre keeps
consistent messaging regarding dry weight monitoring,
as well as medication education, key elements in the
care of patients with HF. Regularly held comprehensive
discharge planning meetings, incorporating the 360o HF
centre care team with the inpatient teams, should be held
to evaluate for need of additional services (such as physical therapy, ocupational therapy, home health, chore
worker, telehealth, CardioMEMS or hospice) and to facilitate the execution of these multidisciplinary discharge
plans. At the time of hospital discharge, every patient
with ADHF must have baseline monitoring parameters
(including estimated ‘dry weight’), instructions for the
patient to call the care coordinator for changes in symptoms, pharmacy education on medication administration
and side effects, a 30-day supply of all discharge medications with prescriptions for refills and a 7-day follow-up
appointment in the HF clinic. Ultimately, randomised
clinical trials are needed to assess feasibility, safety and
effectiveness of inpatient versus outpatient management
of patients with ADHF presenting to the ED.
There are many barriers to creating an effective 360o
HF centre. First and most obvious is the belief that the
costs and reimbursements in the current fee for service
model will not adequately compensate for the aforementioned services. Diuretic administration through
subcutaneous or intravenous route have designated
billable Current Procedural Terminology codes (96365,
96366, 96374 and 96372) for either push or infusion,
with similar reimbursement for both the technical and
the provider fees to many common cardiac procedures,
like echocardiograms or moderate sedation. As of 2019
telemedicine now also has billable codes (99 201 and
99 215 as well as 99452, 99451, 99446, 99447, 99448 and
99449)24 to account for the services provided to monitor
and manage patients with HF via home telehealth and/
or CardioMEMS. Second, there are concerns that this
programme will increase utilisation of medical resources
and costs. However, it is more likely that by preventing
costly inpatient admissions, reducing adverse outcomes
and lost productivity due to ADHF, the costs of a 360o
HF centre will be more than offset. This must be validated through clinical studies comparing the costs and
3
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outcomes of the current standard of care with the 360o
HF centre, which is in line with the ongoing changes
to restructure reimbursements based on performance
metrics rather than the current fee for service model:
paying for health, not for healthcare.
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